AHR is a Zika virus host factor and a candidate target for antiviral therapy
Author(s)
Giovannoni, Federico; Bosch, Irene; Polonio, Carolina Manganeli; Torti, María F.; Wheeler, Michael A.; Li, Zhaorong; Romorini, Leonardo; Rodriguez Varela, María S.; Rothhammer, Veit; Barroso, Andreia; Tjon, Emily C.; Sanmarco, Liliana M.; Takenaka, Maisa C.; Modaresi, Seyed Mohamad Sadegh; Gutiérrez-Vázquez, Cristina; Zanluqui, Nágela Ghabdan; dos Santos, Nilton Barreto; Munhoz, Carolina Demarchi; Wang, Zhongyan; Damonte, Elsa B.; Sherr, David; Gehrke, Lee; Peron, Jean Pierre Schatzmann; Garcia, Cybele C.; Quintana, Francisco J.; ... Show more Show less
DownloadAccepted version (4.208Mb)
Publisher Policy
Publisher Policy
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Terms of use
Metadata
Show full item recordAbstract
Zika virus (ZIKV) is a flavivirus linked to multiple birth defects including microcephaly, known as congenital ZIKV syndrome. The identification of host factors involved in ZIKV replication may guide efficacious therapeutic interventions. In genome-wide transcriptional studies, we found that ZIKV infection triggers aryl hydrocarbon receptor (AHR) activation. Specifically, ZIKV infection induces kynurenine (Kyn) production, which activates AHR, limiting the production of type I interferons (IFN-I) involved in antiviral immunity. Moreover, ZIKV-triggered AHR activation suppresses intrinsic immunity driven by the promyelocytic leukemia (PML) protein, which limits ZIKV replication. AHR inhibition suppressed the replication of multiple ZIKV strains in vitro and also suppressed replication of the related flavivirus dengue. Finally, AHR inhibition with a nanoparticle-delivered AHR antagonist or an inhibitor developed for human use limited ZIKV replication and ameliorated newborn microcephaly in a murine model. In summary, we identified AHR as a host factor for ZIKV replication and PML protein as a driver of anti-ZIKV intrinsic immunity.
Date issued
2020-07Department
Massachusetts Institute of Technology. Institute for Medical Engineering & ScienceJournal
Nature Neuroscience
Publisher
Springer Science and Business Media LLC
Citation
Giovannoni, Federico, Bosch, Irene, Polonio, Carolina Manganeli, Torti, María F, Wheeler, Michael A et al. 2020. "AHR is a Zika virus host factor and a candidate target for antiviral therapy." Nature Neuroscience, 23 (8).
Version: Author's final manuscript
ISSN
1097-6256
1546-1726